PubMed:32736597 / 4631-4927 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T12","span":{"begin":148,"end":151},"obj":"Body_part"},{"id":"T13","span":{"begin":260,"end":263},"obj":"Body_part"}],"attributes":[{"id":"A12","pred":"fma_id","subj":"T12","obj":"http://purl.org/sig/ont/fma/fma24890"},{"id":"A13","pred":"fma_id","subj":"T13","obj":"http://purl.org/sig/ont/fma/fma24890"}],"text":"The primary endpoint/outcome measure for this trial is: for Group 1, the proportion of subjects who become symptomatic and/or swab-positive in each arm within one month of randomization; for Group 2, the proportion of subjects who become swab-negative in each arm within 14 days of randomization."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T5","span":{"begin":148,"end":151},"obj":"Body_part"},{"id":"T6","span":{"begin":260,"end":263},"obj":"Body_part"}],"attributes":[{"id":"A5","pred":"uberon_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/UBERON_0001460"},{"id":"A6","pred":"uberon_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/UBERON_0001460"}],"text":"The primary endpoint/outcome measure for this trial is: for Group 1, the proportion of subjects who become symptomatic and/or swab-positive in each arm within one month of randomization; for Group 2, the proportion of subjects who become swab-negative in each arm within 14 days of randomization."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T53","span":{"begin":148,"end":151},"obj":"http://www.ebi.ac.uk/efo/EFO_0001410"},{"id":"T54","span":{"begin":260,"end":263},"obj":"http://www.ebi.ac.uk/efo/EFO_0001410"}],"text":"The primary endpoint/outcome measure for this trial is: for Group 1, the proportion of subjects who become symptomatic and/or swab-positive in each arm within one month of randomization; for Group 2, the proportion of subjects who become swab-negative in each arm within 14 days of randomization."}

{"project":"LitCovid-sentences","denotations":[{"id":"T33","span":{"begin":0,"end":296},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The primary endpoint/outcome measure for this trial is: for Group 1, the proportion of subjects who become symptomatic and/or swab-positive in each arm within one month of randomization; for Group 2, the proportion of subjects who become swab-negative in each arm within 14 days of randomization."}